CompanyINDPNasdaqNew York, NY

Indaptus Therapeutics, Inc

Indaptus Therapeutics develops the Decoy platform, which uses attenuated, non-pathogenic Gram-negative bacteria to activate innate and adaptive immunity while reducing systemic toxicity.

Stories only

SEC EDGAR ClinicalTrials.gov

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Indaptus extends outside date for $24 million private placement to October 16

Sep 30PartnershipIndaptus Therapeutics, Inc

Indaptus Therapeutics raises $24 million in private placement, revamps ATM agreement

Sep 9PartnershipIndaptus Therapeutics, Inc

Indaptus Therapeutics board member Tim Ruan resigns effective immediately

Sep 4PeopleIndaptus Therapeutics, Inc

Indaptus corrects dilution math in $100M at-the-market offering prospectus

Sep 4FinancingIndaptus Therapeutics, Inc

August 2026

Indaptus halts Decoy20 enrollment, pivots to strategic review after Q2 2026

Aug 13Quarterly updateIndaptus Therapeutics, Inc